Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor

Executive Summary

Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.

You may also be interested in...

Early Stage Science Watch

Scrip scans for early stage research – from bench to clinic – that could lead to novel treatments or changes in therapy recently published in major science journals.

Five Prime Enters Transition Phase; Multiple Trials Planned In Next 12 Months

Five Prime, in partnership with immunotherapy giant Bristol-Myers Squibb, will launch several pivotal trials in the next 12 months for its lead compound cabiralizumab – both in combination with Opdivo in cancer and as a monotherapy in orphan disease PVNS.

A Quick Primer On Roche's Immuno-Oncology Assets

Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts